论文信息 - Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the CheckMate 648 study. - 字舞流文

Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the CheckMate 648 study.

J. Ajani | Y. Doki | Jianming Xu | L. Wyrwicz | S. Motoyama | Chih-Hung Hsu | Ken Kato | T. Ogata | I. Chau | A. Adenis | M. Lei | Y. Kitagawa | I. Xynos | H. Kawakami | E. Holtved | M. Bartolomeo | F. E. Hajbi | K. Kondo | M. F. Braghiroli | Xuan Liu